FATİH KARA, Mahmut Can YAGMURDUR, Bulent GUVENDİ, Kenan BİNNETOGLU, Gulname Findik GUVENDİ, Yasemen ADALİ, Tugba TOYRAN

Comparison of platelet indices in papillary thyroid carcinoma and microcarcinoma

Aim: Papillary thyroid carcinoma (PTC) is the most common primary thyroid malignancy. It is called papillary thyroid microcarcinoma (PTMC) if the nodule is less than 10 mm in diameter. It has been shown that platelets may play an essential role during chronic inflammation, cancer progression, and metastasis. The aim of this study was to examine the value of platelet indices including platelet count, mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in PTC.Material and Methods: 26 patients (19 female, 7 male) with PTC diagnosis were included in the study. The patients were divided into two groups: papillary thyroid microcarcinoma (PTMC) and PTC. All patients who were included in the study were examined for complete blood count parameters.Results: There was no significant difference between the groups in terms of age and gender. Leukocyte count, neutrophil count and percentage, lymphocyte count and percentage, platelet count, plateletcrit, and MPV were not statistically different between groups. PDW were significantly higher in patients with PTC than in those with PTMC.Conclusion: Our results show that patients with PTC have higher PDW levels compared to patients with PTMC. Elevated PDW in PTC may be useful in diagnosis of the disease and for better understanding of its pathogenesis.

PDF

___

Kapsoritakis AN, Koukourakis M, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96(3):776-81.
Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004;99(5):938-45.
Fox JG, Barthold S, Davisson M, Newcomer CE, Quimby FW, Smith A. The mouse in biomedical research: normative biology, husbandry, and models. Amsterdam: Academic Press; 2006:156.
Shi X, Cai W, Zhou Y, Zhang X, Xiong L, Li R, et al. IL-13 upregulates GPIIb expression in megakaryocytic cell lines via STAT6. Anat Rec (Hoboken) 2010;293(9):1470-6.
Cortin V, Garnier A, Pineault N, Lemieux R, Boyer L, Proulx C. Efficient in vitro megakaryocyte maturation using cytokine cocktails optimized by statistical experimental design. Exp Hematol 2005;33(10):1182-91.
Zivancevic-Simonovic S, Mihaljevic O, Majstorovic I, Popovic S, Markovic S, Milosevic-Djordjevic O, et al. Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis. Cancer Immunol Immunother 2015;64(8):1011-9.
Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. Significance of interleukin-6 in papillary thyroid carcinoma. J Thyroid Res 2016;2016:1-12.
Beksac K, Sonmez C, Cetin B, Kismali G, Sel T, Tuncer Y, et al. Evaluation of proinflammatory cytokine and neopterin levels in women with papillary thyroid carcinoma. Int J Biol Markers 2016;31(4):e446-e50.
Li N, Fu S, Cui MM, Niu Y, Li B, Liu ZP, et al. Platelet distribution width and serum albumin levels for discrimination of thyroid cancer from benign thyroid nodules. Asian Pac J Cancer Prev 2017;18(7):1773-7.
Machairas N, Kostakis ID, Prodromidou A, Stamopoulos P, Feretis T, Garoufalia Z, et al. Trends in white blood cell and platelet indices in a comparison of patients with papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions. Endocr Res 2017:1-7.
Yaylaci S, Tosun O, Sahin O, Genc AB, Aydin E, Demiral G, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer. Asian Pac J Cancer Prev 2016;17(4):2321-3.
Dincel O, Bayraktar C. Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma. Bratisl Lek Listy 2017;118(3):153-5.
Mezouar S, Frere C, Darbousset R, Mege D, Crescence L, Dignat-George F, et al. Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thromb Res 2016;139:65-76.
Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al. Platelet “first responders” in wound response, cancer, and metastasis. Cancer Metastasis Rev 2017;36(2)199-213.
Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev 2005;31(6):423-38.
Dideban S, Abdollahi A, Meysamie A, Sedghi S, Shahriari M. Thyroid Papillary Microcarcinoma: Etiology, Clinical Manifestations,Diagnosis, Follow-up, Histopathology and Prognosis. Iran J Pathol 2016;11(1):1-19.
Vuong HG, Duong UN, Altibi AM, Ngo HT, Pham TQ, Tran HM, et al. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect 2017;6(3):R8-R17.
La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015;136(9):2187-95.
Pusztaszeri M, Auger M. Update on the cytologic features of papillary thyroid carcinoma variants. Diagn Cytopathol 2017;45(8):714-30.
Miccoli P, Bakkar S. Surgical management of papillary thyroid carcinoma: an overview. Updates Surg 2017;69(2):145-50.